| Document |
Document Title |
|
WO/2016/077625A1 |
Polymeric carriers for the delivery of therapeutic agents and methods for making and using the same. The polymeric carriers include copolymers, diblock copolymers, polymeric architectures that include the copolymers and diblock copolymer...
|
|
WO/2016/074561A1 |
A microtubule provided with a radionuclide, the microtubule being charged with a filler obtained after the radionuclide has been mixed with a carrier. A preparation method for the microtubule loaded with the radionuclide and/or a drug is...
|
|
WO/2016/072801A1 |
The present invention relates to a method for preparing a radiopharmaceutical and, specifically, to a method for preparing an organic fluoride-aliphatic compound usable as a radiopharmaceutical, to a method for purifying the prepared org...
|
|
WO/2016/072104A1 |
The present invention provides a phosphonium compound indicated by formula (II). Also provided is a production method for a quaternary phosphonium compound labelled with positron emitting radionuclides, that includes a step in which: an ...
|
|
WO/2016/073348A1 |
Described herein is a method of inducing vascular inflammation using modified paramagnetic nanoparticles with improved therapeutic loading efficiency and enhanced circulation properties. The method comprises loading lipophilic agent into...
|
|
WO/2016/067145A1 |
A quantitative imaging system (100) for automating delivery of a radiopharmaceutical and imaging a patient. The system (100) includes a QI controller (102) that controls the operation of the system. The system (100) includes a producer (...
|
|
WO/2016/070001A1 |
Provided herein are embodiments relating to therapeutic applications of B7-H4 antibodies.
|
|
WO/2016/066534A1 |
The present invention relates to a compound of formula (I), wherein R is defined as in the description and in the claims. The compound of formula (I) can be used as radiolabeled ligand.
|
|
WO/2016/067238A1 |
The present application provides quinoline-3-carboxamide compounds covalently linked to a label for use in the diagnosis of an inflammatory disease at local site. The above mentioned compounds can be used to detect or image accumulation ...
|
|
WO/2016/070163A1 |
Certain embodiments are directed to method for synthesizing and using glycoconjugates on the immunodominant epitope Galα(1,3)Galβ(1,4)GlcNAcα (Galα3LNα).
|
|
WO/2016/065145A2 |
"Reversed" carbamate based scaffolds that have high binding affinity to PSMA are disclosed. These scaffolds can be radiolabeled and used for imaging cells and tumors that express PSMA or for cancer radiotherapy. These compounds also can ...
|
|
WO/2016/064379A1 |
This invention relates to porous microparticulate carriers that incorporate radioisotopes to form radiomicroparticles for radiation therapy and imaging. The invention also provides methods of preparing the microparticles and methods of t...
|
|
WO/2016/065322A1 |
The present disclosure provides purified forms of iobenguane and preparations of a precursor to iobenguane, such as a polymer, the polymer comprising a monomer of formula (I) or a pharmaceutically acceptable salt thereof, the preparation...
|
|
WO/2016/062370A1 |
The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer.
|
|
WO/2016/061801A1 |
Disclosed are a method and carrier for targeting amyloid protein based on polypeptides. The carrier is used to transport compounds or medicines through the blood brain barrier of an individual to be bound with amyloid protein in the brai...
|
|
WO/2016/065142A2 |
Carbamate and beta-amino acid urea-based scaffolds that have high binding affinity to PSMA are disclosed. These scaffolds can be radiolabeled and used for imaging cells and tumors that express PSMA or for cancer radiotherapy. These compo...
|
|
WO/2016/062781A1 |
The present invention relates to compounds and methods for imaging pancreatic beta-cells and determination of pancreatic beta-cell mass (BCM). The compounds comprises a peptide having an insulin binding amino acid sequences, a cell pepti...
|
|
WO/2015/190568A9 |
The present invention relates to a medicine for preventing and/or treating stress-induced diseases, said medicine being characterized in that (1S)-2-acetyl-1-(4-chloro-2-methoxyphenyl)-5-fluoro-1,2,3,9-
tetrahydrospiro[β-carboline-4,1'-...
|
|
WO/2016/058056A1 |
The invention discussed in this application relates to hydroxamic acid-based compounds that are useful as imaging agents when bound to an appropriate metal centre, particularly for the imaging of tumours.
|
|
WO/2016/058704A1 |
The invention relates to a compound V for complexing metallic isotopes, comprising a chelator X and one or more targeting vectors conjugated with the chelator X, said targeting vectors having the structure -L1-R1-L2-R2-L3-R3, wherein R3 ...
|
|
WO/2016/058082A1 |
Compounds having a structure of Formula I: (I) or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R1, R2, R3, R4, Z, X and n are as defined herein, and wherein the compound comprises at least one 18F moiety, are provi...
|
|
WO/2016/055941A1 |
The present invention relates to Tau-specific antibodies, fragments thereof, and uses thereof. More specifically, the present invention relates to Tau-specific antibodies, fragments thereof, and conjugates thereof with conjugated to a su...
|
|
WO/2016/057427A1 |
Provided herein is a nanopore structure, which in one aspect is a "carbon nanotube porin", that comprises a short nanotube with an associated lipid coating. Also disclosed are compositions and methods enabling the preparation of such nan...
|
|
WO/2016/050354A1 |
The present invention is related to a bone marrow-derived myeloid progenitor cell (MPC), preferably an isolated bone marrow-derived myeloid progenitor cell (MPC), wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressin...
|
|
WO/2016/051306A2 |
The present invention is directed to a novel compound of Formula 1 wherein the radiolabeled compound of Formula 1 is capable of being used as a radiotracer in PET imaging of a targeted localized tissue and targeted radionuclide therapy o...
|
|
WO/2016/054247A1 |
The invention relates to in vitro methods for measuring the in vivo metabolism of tau in a subject.
|
|
WO/2016/054603A2 |
Provided are methods for altering the distribution of a cell surface antigen. Also provided are compositions for use in the methods, including multivalent meditopes, and methods of producing, using, testing, and screening the same, inclu...
|
|
WO/2016/046793A2 |
This invention relates new radiopharmaceutical conjugates for use in improved methods of diagnosis and treatment of cancer. The radiopharmaceutical conjugate comprises, in sequence: a metabolite that targets tumour cells, bound to a chel...
|
|
WO/2016/047424A1 |
The present invention provides a renal imaging agent comprising a nitroimidazole-type compound or a salt thereof. The renal imaging agent according to the present invention can be used in positron emission tomography.
|
|
WO/2016/049571A1 |
Systems, devices, and methods are provided that facilitate synthesis and analysis of chemical compounds on a convenient and automatable palette-based platform. Palettes utilized for analysis support a variety of functional sites, includi...
|
|
WO/2016/044300A2 |
|
|
WO/2016/044846A1 |
This disclosure relates saccharide analogs such as thiomaltose-based analogs for targeting bacteria and related uses. In certain embodiments, the disclosure relates to methods of transferring a molecule of interest into bacteria comprisi...
|
|
WO/2016/040179A1 |
A method of reducing radiation exposure of a non-cancerous tissue of a patient diagnosed with a cancer includes administering to the patient an agent capable of competing for binding sites on a surface of the non-cancerous tissue, provid...
|
|
WO/2016/038565A1 |
Disclosed are Somatostatin receptor ligands comprising a peptide moiety, pharmaceutical compositions and uses thereof. Disclosed are also synthetic Somatostatin receptor ligands comprising a cyclic peptide moiety and an active agent moie...
|
|
WO/2016/040458A2 |
18F labeled ID01 imaging constructs are constructed for positron emission tomography (PET). Synthetic methodology involves the coupling of a l-fluoro-2-halo-4- aminobenzene and a 4-amino-N-hydroxy-l,2,5-oxadiazole-3-carboximidoyl chlorid...
|
|
WO/2016/033527A1 |
The invention is directed to methods of reducing growth of prostate cancer cells and breast cancer cells, which comprises treating such cancer cells with a combination of androgen or endocrine deprivation therapy (e.g., enzalutamide, abi...
|
|
WO/2016/033190A1 |
A compound represented by the formula (XXIX) or a salt thereof, as shown in FIG. 7, wherein at least one fluorine is fluorine-18, at least one carbon is carbon-11, at least one nitrogen is nitrogen-13, or at least one oxygen is oxygen-15...
|
|
WO/2016/029324A1 |
Novel azasulfuryl-containing peptidomimetics capable of inhibiting CD36 activity are disclosed. Use of these azasulfuryl-containing peptidomimetics for the treatment of CD36-related diseases, disorders or conditions, including TLR2-media...
|
|
WO/2016/030103A1 |
The present invention relates to a kit for radiolabelling a targeting agent with gallium-68. The present invention also relates to the use of said kit for radiolabelling a targeting agent, a method for radiolabelling a targeting agent wi...
|
|
WO/2016/030104A1 |
The present invention relates the use of metal inhibitor in radiolabelling reactions using radioactive metals.
|
|
WO/2016/026046A1 |
A compound of formula (I) as described herein and methods and uses thereof as probes in the mass tagging of biosensors or biologically active materials for use in mass cytometry analysis of tissue samples such as in the detection, labell...
|
|
WO/2016/025786A1 |
A marker for imaging includes a bio-dissolvable material and a contrast agent configured to provide contrast during an imaging procedure. A method can include forming a marker for imaging from a bio-dissolvable material and impregnating ...
|
|
WO/2016/025480A1 |
This disclosure relates to trans-cyclooctene compounds and methods of using the same in bioorthogonal labeling experiments.
|
|
WO/2016/022987A1 |
Disclosed are compositions that contain a plurality of biocompatible self-assembling molecules that transform from isolated molecules or spherical micelles while in blood serum into cylindrical nanofibers in the acidic extracellular envi...
|
|
WO/2016/020791A1 |
The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
|
|
WO/2016/016329A1 |
The application provides polypeptides comprising or essentially consisting of at least one heavy chain variable domain of a heavy chain antibody (VHH) or a functional fragment thereof, wherein said VHH or a functional fragment thereof sp...
|
|
WO/2016/016457A1 |
The present invention shows extremely small iron oxide nanoparticles, 2 nm core size, 68Ga core-doped through a microwave driven synthesis that provides an expedited protocol with radiolabelling efficiency yield of around 90%, optimal fo...
|
|
WO/2016/016021A1 |
The application provides polypeptides comprising or essentially consisting of at least one heavy chain variable domain of a heavy chain antibody (VHH) or functional fragments thereof, wherein said VHH or functional fragment thereof speci...
|
|
WO/2016/018896A1 |
The present disclosure, among other things, provides new technologies for preparation of medical isotope labeled metal(loid) chalcogen nanoparticles for use in medical imaging and/or therapeutic applications. Provided technologies show a...
|
|
WO/2016/009809A1 |
Provided is a novel expression-suppressing nucleic acid molecule for suppressing the expression of a target gene. The expression-suppressing nucleic acid molecule according to the present invention is a single-stranded nucleic acid in wh...
|
